Cargando…
The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1
Alzheimer’s disease (AD) represents a progressive amyloidogenic disorder whose advancement is widely recognized to be connected to amyloid-β peptides and Tau aggregation. However, several other processes likely contribute to the development of AD and some of them might be related to protein-protein...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288020/ https://www.ncbi.nlm.nih.gov/pubmed/32456156 http://dx.doi.org/10.3390/molecules25102439 |
_version_ | 1783545183348981760 |
---|---|
author | Ciccone, Lidia Shi, Chenghui di Lorenzo, Davide Van Baelen, Anne-Cécile Tonali, Nicolo |
author_facet | Ciccone, Lidia Shi, Chenghui di Lorenzo, Davide Van Baelen, Anne-Cécile Tonali, Nicolo |
author_sort | Ciccone, Lidia |
collection | PubMed |
description | Alzheimer’s disease (AD) represents a progressive amyloidogenic disorder whose advancement is widely recognized to be connected to amyloid-β peptides and Tau aggregation. However, several other processes likely contribute to the development of AD and some of them might be related to protein-protein interactions. Amyloid aggregates usually contain not only single type of amyloid protein, but also other type of proteins and this phenomenon can be rationally explained by the process of protein cross-seeding and co-assembly. Amyloid cross-interaction is ubiquitous in amyloid fibril formation and so a better knowledge of the amyloid interactome could help to further understand the mechanisms of amyloid related diseases. In this review, we discuss about the cross-interactions of amyloid-β peptides, and in particular Aβ1-42, with other amyloids, which have been presented either as integrated part of Aβ neurotoxicity process (such as Tau) or conversely with a preventive role in AD pathogenesis by directly binding to Aβ (such as transthyretin, cystatin C and apolipoprotein A1). Particularly, we will focus on all the possible therapeutic strategies aiming to rescue the Aβ toxicity by taking inspiration from these protein-protein interactions. |
format | Online Article Text |
id | pubmed-7288020 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72880202020-06-15 The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1 Ciccone, Lidia Shi, Chenghui di Lorenzo, Davide Van Baelen, Anne-Cécile Tonali, Nicolo Molecules Review Alzheimer’s disease (AD) represents a progressive amyloidogenic disorder whose advancement is widely recognized to be connected to amyloid-β peptides and Tau aggregation. However, several other processes likely contribute to the development of AD and some of them might be related to protein-protein interactions. Amyloid aggregates usually contain not only single type of amyloid protein, but also other type of proteins and this phenomenon can be rationally explained by the process of protein cross-seeding and co-assembly. Amyloid cross-interaction is ubiquitous in amyloid fibril formation and so a better knowledge of the amyloid interactome could help to further understand the mechanisms of amyloid related diseases. In this review, we discuss about the cross-interactions of amyloid-β peptides, and in particular Aβ1-42, with other amyloids, which have been presented either as integrated part of Aβ neurotoxicity process (such as Tau) or conversely with a preventive role in AD pathogenesis by directly binding to Aβ (such as transthyretin, cystatin C and apolipoprotein A1). Particularly, we will focus on all the possible therapeutic strategies aiming to rescue the Aβ toxicity by taking inspiration from these protein-protein interactions. MDPI 2020-05-23 /pmc/articles/PMC7288020/ /pubmed/32456156 http://dx.doi.org/10.3390/molecules25102439 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ciccone, Lidia Shi, Chenghui di Lorenzo, Davide Van Baelen, Anne-Cécile Tonali, Nicolo The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1 |
title | The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1 |
title_full | The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1 |
title_fullStr | The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1 |
title_full_unstemmed | The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1 |
title_short | The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1 |
title_sort | positive side of the alzheimer’s disease amyloid cross-interactions: the case of the aβ 1-42 peptide with tau, ttr, cysc, and apoa1 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288020/ https://www.ncbi.nlm.nih.gov/pubmed/32456156 http://dx.doi.org/10.3390/molecules25102439 |
work_keys_str_mv | AT cicconelidia thepositivesideofthealzheimersdiseaseamyloidcrossinteractionsthecaseoftheab142peptidewithtauttrcyscandapoa1 AT shichenghui thepositivesideofthealzheimersdiseaseamyloidcrossinteractionsthecaseoftheab142peptidewithtauttrcyscandapoa1 AT dilorenzodavide thepositivesideofthealzheimersdiseaseamyloidcrossinteractionsthecaseoftheab142peptidewithtauttrcyscandapoa1 AT vanbaelenannececile thepositivesideofthealzheimersdiseaseamyloidcrossinteractionsthecaseoftheab142peptidewithtauttrcyscandapoa1 AT tonalinicolo thepositivesideofthealzheimersdiseaseamyloidcrossinteractionsthecaseoftheab142peptidewithtauttrcyscandapoa1 AT cicconelidia positivesideofthealzheimersdiseaseamyloidcrossinteractionsthecaseoftheab142peptidewithtauttrcyscandapoa1 AT shichenghui positivesideofthealzheimersdiseaseamyloidcrossinteractionsthecaseoftheab142peptidewithtauttrcyscandapoa1 AT dilorenzodavide positivesideofthealzheimersdiseaseamyloidcrossinteractionsthecaseoftheab142peptidewithtauttrcyscandapoa1 AT vanbaelenannececile positivesideofthealzheimersdiseaseamyloidcrossinteractionsthecaseoftheab142peptidewithtauttrcyscandapoa1 AT tonalinicolo positivesideofthealzheimersdiseaseamyloidcrossinteractionsthecaseoftheab142peptidewithtauttrcyscandapoa1 |